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T
ype 2 diabetes is a complex meta-
bolic disorder characterized by
hyperglycemia arising from a com-
bination of insufﬁcient insulin secretion
together with resistance to insulin action.
The incidence and prevalence of type 2
diabetes are rising steadily, fuelled in part
by a concomitant increase in the world-
wide rates of obesity. As longitudinal
studies of type 2 diabetes provide evi-
dence linking improved glycemic control
with a reduction in the rates of diabetes-
associated complications, there is consid-
erable interest in the therapy of type 2
diabetes (Fig. 1), with a focus on the de-
velopment and use of new agents that ex-
hibit improved efﬁcacy and safety relative
to current available medicines.
Althoughthenumberofpatientswith
type 2 diabetes that successfully achieve
target levels of A1C is steadily improving,
a substantial number of subjects continue
to fall short of acceptable treatment goals,
leavingthemathighriskfordevelopment
of diabetes-associated complications (1).
More importantly, a large number of sub-
jects with type 2 diabetes fail to achieve
targetvaluesforglucose,lipids,andblood
pressure, with only 12.2% of patients
meeting target values despite recent im-
provements in therapeutic agents target-
ing hyperglycemia, dyslipidemia, and
hypertension (2). The development of
multiple new agents for the treatment of
type2diabeteshasbroadenedtheoptions
for patient-speciﬁc therapy. However, no
currentlyavailableagentsexhibittheideal
proﬁle of exceptional glucose-lowering
efﬁcacy to safely achieve target levels of
glycemia in a broad range of patients.
Hence, highly efﬁcacious agents that ex-
hibit unimpeachable safety, excellent tol-
erability, and ease of administration to
ensure long-term adherence and that also
clearly reduce common comorbidities
and complications of diabetes are clearly
needed (Fig. 1). Furthermore, most pa-
tients require combination therapy to
achieve effective control of their disease
(3). Recommended initial therapy gener-
ally includes comprehensive lifestyle
management and patient education com-
bined with metformin therapy. Although
metformin is widely accepted as the pre-
ferred agent for the initial treatment of
type 2 diabetes, there remains consider-
able uncertainty and lack of consensus in
regard to choice of additional agents that
need to be added to metformin to opti-
mize glycemic control.
Recent recommendations have high-
lighted the use of insulin, sulfonylureas,
and thiazolidinediones as second-line
therapies because of their proven efﬁcacy
in long-term outcome studies. Neverthe-
less, more recent studies involving in-
tensiveuseofthesetherapiesinpatients
with clinical cardiovascular disease or
multiple risk factors to achieve lower
target glucose levels were associated
with hypoglycemia, bone fractures,
hospitalization for congestive heart fail-
ure, weight gain, and, in some analyses,
increased mortality with modest beneﬁt
on rates of myocardial infarction. This
has led to a re-examination of treatment
recommendations to minimize the risk
ofcardiovascularmorbidityandmortal-
ity (3,4) and speciﬁcally an interest in
incretin-based therapies in this regard.
Incretin-based therapies:
mechanisms of action and beneﬁts
Thetwomostrecentlyapprovedclassesof
therapeutic agents for the treatment of
type 2 diabetes, glucagon-like peptide-1
(GLP-1) receptor (GLP-1R) agonists and
dipeptidyl peptidase-4 inhibitors (DPP-
4i), exert their actions through potentia-
tion of incretin receptor signaling.
Incretinsaregut-derivedhormones,prin-
cipally GLP-1 and glucose-dependent in-
sulinotropic peptide (GIP), that are
secreted at low basal levels in the fasting
state. Circulating levels increase rapidly
and transiently following food ingestion.
As native GLP-1 displays a very short cir-
culating half-life due to renal clearance
and NH2-terminal degradation by the
enzyme DPP-4, degradation-resistant
GLP-1R agonists have been developed.
Exendin-4, a GLP-1R agonist structurally
related to the native gut peptide, was ap-
proved for the treatment of type 2 diabe-
tes in the U.S. in April 2005 and is
currently administered as a subcutaneous
injection (10 g twice daily) for use as
monotherapy in subjects not achieving
adequate glycemic control on lifestyle
modiﬁcation alone or one or more oral
agents. Liraglutide is an investigational
human acylated GLP-1R agonist ap-
proved in Europe that binds nonco-
valently to albumin and exhibits a more
prolonged duration of action suitable for
once daily administration. A longer-
acting microsphere preparation of ex-
enatide suitable for once weekly
administration, exenatide (once weekly),
has also been studied in controlled clini-
cal trials and appears to be somewhat
more effective compared with exenatide
twice daily (5).
Sitagliptin was the ﬁrst DPP-4i ap-
proved in the U.S. in October 2006. It
exerts its glucoregulatory actions through
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ing to potentiation of GLP-1 and GIP ac-
tion (6). Sitagliptin is administered as a
single100-mgdailytableteitherasmono-
therapy or in combination therapy with
oral antidiabetic agents. Sitagliptin is well
tolerated and is not associated with nau-
sea or vomiting as the levels of endoge-
nous intact GLP-1 achieved following
DPP-4 inhibition are at the upper limit of
the normal physiological range; hence, it
is not sufﬁcient to induce an aversive re-
sponse.Conversely,DPP-4itherapyisnot
associated with inhibition of gastric emp-
tyingorweightloss,andtheavailabledata
suggest that long-acting GLP-1R agonists
achieve more potent control of glycemia,
relativetoDPP-4i,duetomorepotentand
sustained GLP-1R activation. Vildaglip-
tin, a second DPP-4i, is approved in
Europe and other countries, while saxa-
gliptin has recently been approved in the
U.S. and several other DPP-4i are under
regulatory review.
GLP-1R agonists control blood glu-
cose through regulation of islet function,
principallywiththestimulationofinsulin
and inhibition of glucagon secretion (7).
Notably, these GLP-1R–dependent ac-
tions are glucose dependent, thereby
minimizing the risk of hypoglycemia in
the absence of concomitant sulfonylurea
therapy. GLP-1R activation also inhibits
gastricemptyingandreducesfoodintake,
leading to weight loss in the majority of
treated subjects (8). The GLP-1R is ex-
pressed in cardiomyocytes and endothe-
lial cells, and preclinical studies
demonstrate that GLP-1R activation is as-
sociated with substantial cardioprotec-
tion and reduced infarct size in
experimental models of coronary artery
ischemia (9,10). Limited evidence sug-
gests that GLP-1 may also preserve ven-
tricular function and improve outcomes
in human subjects with heart failure or
myocardial infarction (11,12). Moreover,
both exenatide and liraglutide reduce
blood pressure, body weight, and plasma
lipid proﬁles in subjects with type 2 dia-
betes (13), raising the hope that long-
term treatment with these agents may
reduce the incidence of cardiovascular
events. Intriguingly, the GLP-1 metabo-
lite, GLP-1 (9–36), also exerts cardiopro-
tective actions in preclinical studies
through mechanisms independent of the
known GLP-1R (14); hence, ongoing re-
search is directed at understanding the
complexity of incretin biology in the car-
diovascular system and the potential for
incretin-based therapies to differentially
modulate cardioprotective signals in the
diabetic heart and blood vessel in vivo
(15). The principal treatment-related ad-
verse events associated with exenatide
and liraglutide therapy are nausea and
vomiting, which generally diminish over
time (13). Analysis of the antidiabetic ac-
tions pursuant to GLP-1 administration
has demonstrated that activation of the
GLP-1R for 24 h provides more sustained
and potent control of glycemia relative to
shorter periods of GLP-1R agonism (16).
In contrast, sustained GLP-1R activation
may be associated with a modest reduc-
tion in control of postprandial glycemia
(5,13), observations of interest to scien-
tists studying the link between postpran-
dial glucose and the development of
cardiovascular morbidity and mortality.
As exenatide requires twice daily admin-
istration and does not provide 24-h
GLP-1Ractivation,therehasbeenconsid-
erable interest in development of GLP-1R
analogueswithmoreprolongeddurations
ofaction(Fig.2)suitableforonce-dailyor
once-weeklyadministration(17).Consis-
tent with the notion that continuous
GLP-1R activation is required for optimal
glucoregulation, liraglutide administered
once daily and exenatide administered
once weekly appear to be more potent
glucose-loweringagents,relativetotwice-
daily exenatide (5,13). Furthermore, they
seem to be associated with better tolera-
bility and patient-reported outcomes as
well as trends toward greater beneﬁt on
cardiovascular disease risk factors (Fig.
Figure 1—Relative comparison of properties exhibited by different classes of agents approved for the treatment of type 2 diabetes. CVD, cardio-
vascular disease; TG, triglycerides; CHF, congestive heart failure. A1C reduction depends on starting A1C.
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acting investigational GLP-1R agonists
being developed for the treatment of type
2diabetes(8).Severalrecentreviewshave
emphasized the mechanisms of action
and clinical results obtained in trials ex-
amining the efﬁcacy of incretin-based
therapies (8,17). Herein we examine ad-
verse events and safety concerns associ-
ated with these agents.
Adverse events associated with GLP-
1R agonists
Acute pancreatitis. Pancreatitis has
been reported as a rare side effect of ex-
enatide therapy principally through post-
marketing surveillance. There are many
risk factors and predisposing causes for
acute pancreatitis, as well as over 200
drugs linked to the development of acute
pancreatitis.Theincidenceofpancreatitis
varies considerably among drugs, being
relatively common for individuals taking
6-mercaptopurine and azathioprine (2–
5%),butveryuncommonforsteroidsand
thiazide diuretics. The severity of the dis-
ease also varies; pancreatitis induced by
6-mercaptopurine is often quite severe,
whilethatcausedbycholinesteraseinhib-
itors is usually mild. There are only two
circumstancesinwhichthemechanismof
drug-induced disease is understood,
drugs that cause hypertriglyceridemia
(e.g., some HIV-protease inhibitors, es-
trogens, isotrentinoin) and drugs that are
mitochondrial toxins. Drugs are not
thought to cause chronic pancreatitis
(with the exception of alcohol and smok-
ing), although they have the theoretical
potential to do so. Numerous animal
models for pancreatitis have been devel-
oped; however, drugs that are associated
with pancreatitis in humans rarely cause
disease in rodents. Whether these spe-
cies-speciﬁc observations reﬂect differ-
ences in drug metabolism, pancreatitis
responses including inﬂammation, or the
factthatsomedrugsmayactassensitizers
and require other factors to cause disease,
remains unclear.
ClinicaldatarelatingGLP-1Ragonists
and DPP-4i to pancreatitis come from a
limited number of case reports, the U.S.
Food and Drug Administration’s (FDA)
adverse event reporting system, and clin-
ical trial records from pharmaceutical
companies. A summary of initial 30 cases
of individuals taking exenatide who de-
veloped acute pancreatitis was published
in 2008 (18). The authors noted that in
least 90% of these subjects, there were
otherfactorsthatcouldpredisposethein-
dividuals to pancreatitis. Rechallenge, a
standard measure for assigning causality
in drug-induced pancreatitis, was per-
formed in only three patients but associ-
ated with recurrence of symptoms in
each. However, the recurrence of symp-
tomswithrechallengewasreportedtooc-
cur only after weeks in some patients. In
most patients with drug-induced pancre-
atitis, rechallenge usually causes disease
within days. Subsequently, hemorrhagic
pancreatitis and several deaths have been
reported to the FDA in patients who pre-
viously used exenatide and similar cases
but no deaths have been reported in pa-
tients treated with sitagliptin (19). A re-
cent study used insurance records to
determine that the risk of pancreatitis for
subjects followed up to a year was 0.12%
and0.13%withsitagliptinandexenatide,
respectively (20). These relative risks did
not differ from a control cohort treated
with metformin or glyburide. Data from
the manufacturer of liraglutide reported a
low incidence of acute pancreatitis (0.8
cases/1,000 patient-years). Notably, anal-
ysis of pancreatitis in subjects with type 2
diabetes suggests that their risk is in-
creased threefold over nondiabetic sub-
jects(21).Sinceonlyafractionofthisrisk
could be attributed to biliary pancreatitis,
it seems likely that other factors such as
obesity and hypertriglyceridemia might
contribute to the increased risk in this
population.
Several experimental studies have ex-
amined the effects of incretin-based
agents on the pancreas in animal models.
Koehler et al. (22) found no evidence of
pancreatitis in mice treated with the
GLP-1R agonist exendin-4 alone and no
GLP-1R–dependent enhancement of
pancreatitis responses in the caerulein-
hyperstimulation model. In contrast,
Nachnani et al. (23) detected histological
evidence for acinar inﬂammation, cell
drop-out and possible ﬁbrosis and in-
creased levels of serum lipase in Sprague-
Dawley rats treated with exendin-4 for 75
Figure 2—Comparison of features associated with exenatide twice daily versus the properties of the emerging class of long-acting GLP-1R agonists
that achieve more prolonged and sustained GLP-1R activation. CVD, cardiovascular disease.
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examined the effects of sitagliptin in hu-
man islet amyloid polypeptide (HIP)
transgenic diabetic rats. The investigators
reported that one of eight HIP rats receiv-
ing the drug developed acute pancreatitis
and noted extensive pancreatic ductal
proliferation and metaplasia and accom-
panying ﬁbrosis in three HIP rats treated
with sitagliptin. Some of the histological
ﬁndings from the latter two studies were
very similar, and reminiscence of changes
was seen with chronic pancreatitis. The
animal studies raise several confounding
issues, namely might there be differences
in pancreatitis responses between
GLP-1R agonists and DPP-4i in humans
versus rodents and in speciﬁc diabetic
versus nondiabetic preclinical models?
Though the relevance of the HIP trans-
genicratmodeltohumandiseaseremains
unclear, that study does suggest that
DPP-4i might induce pancreatic metapla-
sia under speciﬁc experimental condi-
tions. In summary, the clinical and
experimental data linking GLP-1R ago-
nists and DPP-4i to pancreatitis are still
incomplete. More information is required
to allow one to determine whether these
agents substantially increase the risk of
acute pancreatitis and whether such dis-
easetendstobesevere.However,patients
receiving these medications will need to
undergo continued surveillance for pan-
creatitis and clinicians should carefully
exclude other causes of acute pancreatitis
when it occurs in subjects receiving these
drugs. Although the diagnosis of drug-
induced pancreatitis would ideally be as-
sociated with conﬁrmatory clinical data
following drug rechallenge, physicians
should exercise caution before consider-
ing a trial of drug rechallenge. As GLP-1R
agonists may also affect smooth muscle
responses and may regulate cholangio-
cyte function (25), their effects on the bil-
iary tract and gallstone formation should
also be examined.
Issues linking these agents with pan-
creatic metaplasia and chronic pancreati-
tis,asnowsuggestedbytwoexperimental
studies, present a different challenge.
Longer-term experimental studies using
different GLP-1R agonists and DPP-4i in
several species and experimental models
of diabetes need to be undertaken to help
clarify the importance of these ﬁndings.
Hence, monitoring of pancreatic function
and pancreatic disease in humans treated
with GLP-1R agonists and DPP-4i in on-
going long-term prospective controlled
clinical trials seems prudent.
Medullary thyroid cancer. Medullary
thyroid carcinoma (MTC) is an uncom-
mon neuroendocrine malignancy with an
estimated U.S. annual incidence of fewer
than 1,000 persons and a lifetime risk of
developmentof0.013%(26).Whendiag-
nosed early and still conﬁned to the thy-
roidgland,thelong-termsurvivalofMTC
is nearly 100% (27). About 25% of MTCs
occur as part of an inherited autosomal
dominant syndrome, either multiple en-
docrineneoplasiatypeIIorfamilialMTC,
and virtually all familial tumors are
caused by inherited mutations in the RET
proto-oncogene. Of sporadic MTCs, at
least40%areassociatedwithsomaticmu-
tationsandRET,andprognosisisworsein
those mutated tumors.
ThehistologicalprecursorstoMTCin
the inherited syndromes are well de-
scribed, beginning with C-cell hyperpla-
sia, leading to nodular C-cell hyperplasia,
and then eventually to MTC. However,
among the sporadically occurring MTCs,
theroleofthishistologicalsequenceisnot
deﬁned, and the exact distinction be-
tween neoplastic and non-neoplastic C-
cell hyperplasia is controversial (28,29).
As a tumor derived from C-cells, MTCs
generally secrete calcitonin, and high se-
rum levels of calcitonin (100 pg/ml) are
nearly 100% speciﬁc for the presence of
MTC(30,31).Nonetheless,thespeciﬁcity
of serum calcitonin concentrations be-
tween the upper end of the reference
rangeand100pg/mlisconsiderablymore
limited. Other etiologies of mild degrees
of hypercalcitoninemia include lympho-
cytic thyroiditis, chronic renal insufﬁ-
ciency, pancreatitis, hypercalcemia,
hypergastrinemia (of any etiology), and
even the postprandial state (31,32). Stim-
ulation of calcitonin release with penta-
gastrin infusion has long been used to
distinguish neoplastic from non-
neoplastic causes of mild hypercalci-
toninemia; however, pentagastrin is no
longer available for human use in the
U.S., and the diagnostic accuracy of test-
ing with alternative stimulants such as
calcium infusion remains to be estab-
lished (31).
Animal models of MTC have limita-
tions in regard to the biology and epide-
miology of human MTC. Rats develop
spontaneous age-related C-cell lesions at
remarkably high frequency, especially
nodular C-cell hyperplasia. Sporadic
MTCoccursin0.5–1%ofmostratspecies
evaluated, with increased frequency in
males and with advancing age; spontane-
ous RET mutations have not been re-
ported, and some typical histological
features of human MTC are generally
lacking. Mice develop spontaneous MTC
less frequently, and most animal models
in use are either transgenic or xenografts
of the well-characterized TT cell line.
Food intake links incretin secretion
withstimulationofcalcitoninsecretionin
rodents, potentially via GLP-1 receptors
expressed on rodent MTC cell lines, and
GLP-1 stimulates calcitonin release in ro-
dents in vivo (33–35). Analysis of data
reported at the 2 April 2009 FDA Advi-
sory Committee review of liraglutide re-
vealed that preclinical toxicology studies
with liraglutide reported C-cell hyperpla-
sia and MTC with increasing exposure to
liraglutide.Atthehighestdrugexposures,
MTCwasreportedin14%ofmaleand6%
offemaleSprague-Dawleyrats,whichwas
above the rates observed in untreated rat
controls.C-celllesionswerealsoreported
to be more common with liraglutide in
CD-1 mice, albeit at much lower frequen-
cies; no C-cell lesions were described in
the cynomologous monkey. In contrast,
once-daily administration of exenatide in
rodents is associated with a high fre-
quency of nodular C-cell lesions but no
carcinomas were reported (36). In safety
monitoring of multiple liraglutide clinical
trials, many patients with undetectable
calcitoninlevelsbeforeinitiationofinves-
tigational (liraglutide, placebo, or active
comparator) therapy were found to have
levels that rose into the mid-reference
normal range; rare patients developed
mild hypercalcitoninemia during ther-
apy. Across the trials, six patients were
found to have C-cell ﬁndings at thyroid-
ectomy following therapy (36). Of these
patients, four were in liraglutide treat-
mentarms,butthreeofthesehadelevated
calcitonin levels before initiation of treat-
ment.Theremainingtwopatientswerein
the active comparator arms of trials, and
one had an elevated calcitonin level be-
fore treatment. This single patient had
MTC and was treated with an active non-
GLP-1–based comparator; the patient
had a markedly elevated calcitonin level
before initiating non-GLP-1–based com-
parator therapy. All of the remaining pa-
tients who underwent thyroidectomy for
hypercalcitoninemia were reported to
have C-cell hyperplasia. According to the
FDA brieﬁng documents, no cases of C-cell
lesions have been documented by histol-
ogy in patients treated with exenatide.
Several cases of papillary thyroid cancer
have also been reported in the liraglutide
clinical development program; however,
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histopathologic identiﬁcation of the le-
sions, together with the lack of biological
plausibility, suggest that this is an inci-
dental ﬁnding not directly related to ther-
apy with GLP-1R agonists.
In summary, rodents exposed to lira-
glutide and exenatide develop C-cell le-
sions at relatively high frequency,
although the currently available data sug-
gest that rodent MTC may be speciﬁc to
long-acting GLP-1R agonists, likely due
to sustained GLP-1R activation. Because
of the historic difﬁculty of distinguishing
neoplasticandnon-neoplasticformsofC-
cell hyperplasia in both rodents and hu-
mans,thediagnosticsigniﬁcanceofC-cell
hyperplasia is unclear. Minimal eleva-
tions of calcitonin levels are very nonspe-
ciﬁc, and available methods of dynamic
testing add little to clarify the etiologies.
Given the extreme rarity of MTC in hu-
mans,thenumbersofpatientswhowould
needtobetreatedfor10yearstoyieldone
additional case of MTC may be extremely
high (35–55,000 if risk is doubled; 10–
15,000 if risk is quintupled). Moreover,
the differences in rodent versus human
C-cell biology with regard to responsivity
to GLP-1R activation raise important
questions about the suitability of mice
and rats as models for understanding the
effects of GLP-1R agonists on human
C-cells.
Summary and conclusions
Incretin-based therapies provide new op-
tions for the treatment of type 2 diabetes
and enable intensiﬁcation of therapy
while controlling body weight through
mechanisms associated with a low rate of
hypoglycemia. Investigational long-
acting GLP-1R agonists require less fre-
quent administration and appear to be
more potent with respect to A1C reduc-
tion than twice-daily exenatide or once-
daily sitagliptin with respect to A1C
reduction. These long-acting GLP-1R
agonists have considerable potential as
antidiabetic therapies as they not only
lower glucose as or more effectively than
other noninsulin antihyperglycemic ther-
apies, they do so in concert with weight
loss, improvement in cardiovascular dis-
ease risk factors, and with very low risk of
hypoglycemia. However, two safety is-
sues have been raised—pancreatitis and
medullary carcinoma of the thyroid.
The relationship between the use of
incretin therapy and the development of
pancreatitis remains unclear. These
agents may not substantially increase the
risk of acute pancreatitis in humans and
might not affect the risk at all. The rele-
vance to humans of the pancreatic meta-
plasia observed with these agents in two
oftherodentstudiesisunknown.Contin-
ued clinical monitoring and more re-
searcharerequiredtoclarifytheactionsof
GLP-1R agonists and DPP-4i on the nor-
mal and diabetic exocrine pancreas.
GLP-1R activation stimulates calcito-
nin secretion and promotes the develop-
ment of C-cell hyperplasia and medullary
thyroid cancer in rodents but not in mon-
keys, and the actions of GLP-1R agonists
on human C-cells remain uncertain. Be-
cause of the rarity of medullary carci-
noma of the thyroid and the lack of
speciﬁcityofclinicalmarkers,screening
strategies, except in the setting of famil-
ial syndromes, almost certainly would
be associated with an increase in mor-
bidity and perhaps mortality as a result
of false positives.
Taken together, the available evi-
dence supports the use of incretin-based
therapies for patients requiring effective
control of glycemia and body weight
while minimizing the risk of hypoglyce-
mia.Ongoingscrutinyandfurtherstudies
are required to clarify the potential signif-
icance of reports of pancreatic injury, in-
cluding pancreatitis and metaplasia, and
rodent medullary thyroid cancer for hu-
man subjects treated with GLP-1R ago-
nists and DPP-4i.
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